Identification of subgroups of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone plus prednisone at low vs. high risk of radiographic progression: An analysis of COU-AA-302

Citation:

Martin LJ, Alibhai SMH, Komisarenko M, et al. Can Urol Assoc J. 2019 Jun;13(6):192-200. PMID: 30407155; PMCID: PMC6570594.